NOSSAMAN LLP for AMERISOURCEBERGEN CORPORATION (FORMERLY "AMERISOURCEBERGEN SPECIALTY GROUP")
A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 1st Quarter - Report (this page) | Apr 20, 2018 | $30,000 | Replaced |
| 1st Quarter - Report | Apr 20, 2018 | $30,000 | Yes |
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Taxation/Internal Revenue Code TAX
Repeal of LIFO (Last in, First Out), H.R. 1 Tax Cuts and Jobs Act
| Lobbyist | Covered position, as disclosed |
|---|---|
| SHELBY LYNNE HAGENAUER | — |
| BRENT HEBERLEE | — |
| TIMOTHY W JENKINS | — |
| SHERRY HARPER WIDICUS | — |
Medicare/Medicaid MMM
Legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price (ASP) generally (in the context of deficit reduction); Medicare Program Part B Drug Payment Model.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SHELBY LYNNE HAGENAUER | — |
| BRENT HEBERLEE | — |
| TIMOTHY W JENKINS | — |
| SHERRY HARPER WIDICUS | — |
Pharmacy PHA
Medicare Prompt Pay Discount Exclusion, legislation to ensure more appropriate general payment amount for drugs & biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Proposals to exclude cancer drugs from sequestration cuts. Medicare Program Part B Drug Payment Model. Legislation to prevent and reduce prescription drug abuse, Pharmaceutical compounding and implementation of the Drug Quality Security Act. S. 1960- A bill to repeal the amendments made to the Controlled Substances Act by the Ensuring Patients Access and Effective Drug Enforcement Act of 2016
| Lobbyist | Covered position, as disclosed |
|---|---|
| SHELBY LYNNE HAGENAUER | — |
| BRENT HEBERLEE | — |
| TIMOTHY W JENKINS | — |
| PAUL S QUINN | — |
| SHERRY HARPER WIDICUS | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.